$18.24
Live
Insights on Longboard Pharmaceuticals Inc
In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 107.8%
2.25%
Downside
Day's Volatility :5.81%
Upside
3.65%
80.26%
Downside
52 Weeks Volatility :87.21%
Upside
35.2%
Period | Longboard Pharmaceuticals Inc | Index (Russel 2000) |
---|---|---|
3 Months | -11.83% | 0.0% |
6 Months | 378.03% | 0.0% |
1 Year | 167.0% | 0.0% |
3 Years | 127.25% | -22.6% |
Market Capitalization | 755.1M |
Book Value | $8.07 |
Earnings Per Share (EPS) | -2.25 |
Wall Street Target Price | 41.22 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.3% |
Return On Equity TTM | -30.04% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -62.9M |
Diluted Eps TTM | -2.25 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.86 |
EPS Estimate Next Year | -2.28 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.48 |
What analysts predicted
Upside of 125.99%
Sell
Neutral
Buy
Longboard Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Longboard Pharmaceuticals Inc | -8.11% | 378.03% | 167.0% | 127.25% | 13.69% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Longboard Pharmaceuticals Inc | NA | NA | NA | -1.86 | -0.3 | -0.19 | NA | 8.07 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Longboard Pharmaceuticals Inc | Buy | $755.1M | 13.69% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Farallon Capital Management, L.L.C.
Cormorant Asset Management, LLC
T. Rowe Price Associates, Inc.
Vanguard Group Inc
FMR Inc
Polar Capital Holdings PLC
longboard pharmaceuticals is a team driven to deliver novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. longboard's proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. longboard is evaluating lp352, a next-generation 5-ht2c agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or dees. longboard is also evaluating lp143, a centrally acting, full agonist of the cannabinoid type 2 receptor (cb2), and lp659, a centrally acting, next-generation, highly selective s1p receptor modulator.
Organization | Longboard Pharmaceuticals Inc |
Employees | 50 |
CEO | Mr. Kevin R. Lind |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$18.24
-3.65%
Keyarch Acquisition Corp
$18.24
-3.65%
Connexa Sports Technologies Inc
$18.24
-3.65%
Us Value Etf
$18.24
-3.65%
First Wave Biopharma Inc
$18.24
-3.65%
Global X Msci Next Emerging
$18.24
-3.65%
Fat Projects Acquisition Corp
$18.24
-3.65%
Capital Link Global Fintech
$18.24
-3.65%
Applied Uv Inc
$18.24
-3.65%